The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

ConditionCLL

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorPeking University People's Hospital

About this trial

This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Eligibility criteria

Qualifiers

1. Patients aged ≥18 years old

2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL [International Workshop on Chronic Lymphocytic Leukemia] criteria)；

3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;

4.Prior or current use of Zanubrutinib for ≥3 months

Disqualifiers

None

Trial design

Treatments tested in this trial

Zanubrutinib

Treatment groups

No treatment groups listed

Sponsors and collaborators

Peking University People's Hospital

Lead sponsor

Source ClinicalTrials.gov